Creamy Latte Powder Delivers Convenience Plus Sustained Daily EnergyBOULDER, Colo., June 11, 2025 /PRNewswire/ -- Laird Superfood, Inc. (NYSE: LSF), a leader in functional coffee, creamers, and superfood products made with simple, minimally processed ingredients, has launched Laird Superfood Protein Instant Latte, an all-in-one powder-to-latte mix containing 10 grams of protein per serving from a proprietary blend of pea, hemp and pumpkin seed protein, naturally occurring MCTs from coconut, organic Lion's M ...

Kymera Therapeutics (KYMR) FY Conference June 10, 2025 03:20 PM ET Speaker0 Hi, Speaker1 everyone. Good afternoon. Thanks so much for joining us. I'm Andrea Newkirk, one of the biotech analysts here at GS. And I'm really pleased to be joined by Nella Manolfe, founder, president, and CEO of Chimera. Thanks so much. Speaker0 Thanks for having us. Speaker1 Yeah, of course. So maybe before we dig into the data that you just presented last week for your STAT6 program, I thought maybe we could start with a overvi ...

Vaxcyte (PCVX) FY Conference June 10, 2025 01:20 PM ET Speaker0 All right. Great. Let's let's kick off our next session. Very pleased to have the management team of Backside here with us, Grant Pickering, CEO and Andrew Guggenheim, CFO. Grant and Andrew, welcome, and thank you for being here. Thank you for having us, Assad, and great to be here. Great. So I guess maybe we can just start at a very high level. In nutshell, for those who perhaps aren't familiar with the Vaxide story, maybe just give us a quick ...

Industry Overview - The Zacks Food – Meat Products industry is experiencing strong growth due to increasing consumer demand for high-protein foods and a focus on health and wellness [2][3] - Companies are diversifying product portfolios, boosting production capacity, and investing in innovative plant-based meat alternatives to remain competitive [2][3] Major Trends - There is a significant increase in demand for high-protein diets, driven by health consciousness among consumers, particularly fitness enthusiasts [6] - The popularity of plant-based meat alternatives is rising as consumers seek healthier options with minimal artificial ingredients [7] - Meat companies are implementing strategic expansions through mergers, acquisitions, and capacity enhancements to improve market presence [8][9] Cost Challenges - Rising input costs, including feed, raw materials, transportation, and labor, are straining operations and increasing production expenses [10][11] - Persistent inflation is affecting consumer behavior, leading to more frequent store visits but lower purchase volumes, which may impact sales and profitability [11] Industry Performance - The Zacks Food – Meat Products industry has underperformed the broader Zacks Consumer Staples sector and the S&P 500 over the past year, declining by 7.8% compared to the sector's growth of 3% and the S&P 500's rise of 11.6% [15] - The industry is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 12.50X, significantly lower than the S&P 500's 21.83X and the sector's 17.80X [16] Company Highlights - **Tyson Foods**: A leading player in the protein industry with a diversified multi-protein strategy, strong brand recognition, and a focus on digital transformation [17][18] - **Hormel Foods**: Growth driven by a strong Foodservice segment and innovation in product offerings, with a focus on operational efficiency through its Transform and Modernize initiative [21][22] - **Pilgrim's Pride**: A major producer of chicken and pork products, focusing on sustainable growth through product diversification and strategic investments in capacity and technology [24][25]

PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to 48 months. This shelf-life extension applies to the 50mg tablet strength of MASIVET® currently available in the EU. MASIVET® is currently approved for the treatment of non-resectable dog mast ...

[Music] The Scripps Research Institute was founded in 1924 and since then has grown to be one of the top research institutions in the United States. We study how viral antigens interact with the immune system to inform vaccine and therapeutic design. A lot of our research is basic science.So we're looking at how we stabilize proteins, what these proteins look like, where they're incorporated in the actual viruses or other things. The biggest challenge for us in our field started with the advent of direct el ...

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...

Industry Overview - The Zacks Food – Meat Products industry is experiencing strong growth due to increasing consumer demand for high-protein foods and a focus on health and wellness [1] - The industry includes companies that manufacture, process, market, and distribute a wide range of meat products, including chicken, pork, beef, and plant-based meats [3] - Major trends include increased protein demand and the rise of plant-based alternatives, driven by health consciousness and dietary preferences [4] Company Performance - Leading companies like Tyson Foods, Hormel Foods, and Pilgrim's Pride are well-positioned for long-term growth despite challenges such as rising input costs and operational expenses [2] - Tyson Foods has a diversified multi-protein strategy and is leveraging digital transformation to optimize supply chain efficiency [16] - Hormel Foods is focusing on innovation and operational efficiency through its Transform and Modernize initiative [20] - Pilgrim's Pride is enhancing profitability through strategic investments and effective cost management strategies [24] Market Trends and Challenges - The industry is facing significant cost-related challenges, including rising prices for feed, raw materials, and labor, which are impacting profit margins [6] - Consumer behavior is shifting, with shoppers making more frequent store visits but purchasing less per trip due to tighter household budgets [6] - The industry's performance has underperformed the broader Zacks Consumer Staples sector and the S&P 500 over the past year, declining 7.8% compared to the sector's growth of 3% and the S&P 500's rise of 11.6% [10] Valuation Metrics - The industry is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 12.50X, compared to the S&P 500's 21.83X and the sector's 17.80X [13] - Over the past five years, the industry's P/E ratio has ranged from a high of 21.76X to a low of 12.24X, with a median of 16.55X [13] Future Outlook - The Zacks Industry Rank for the Food – Meat Products industry is 93, placing it in the top 38% of over 250 Zacks industries, indicating encouraging near-term prospects [7][8] - Analysts are gaining confidence in the earnings growth potential of the industry, as evidenced by positive earnings estimate revisions [9]

Core Viewpoint - Nurix Therapeutics is set to present new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) at the European Hematology Association Congress, highlighting the company's focus on targeted protein degradation medicines for cancer treatment [1][5]. Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [5]. - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on innovative drug design [5]. - Nurix is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline, supported by a fully AI-integrated discovery engine [5]. Clinical Trial Information - Bexobrutideg (NX-5948) is an investigational, orally bioavailable small molecule degrader of BTK, currently evaluated in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [4]. - The ongoing clinical trial can be accessed for additional information at clinicaltrials.gov (NCT05131022) [4]. Upcoming Presentations - The company will host a webcast conference call on June 12, 2025, to discuss the new data from the Phase 1 clinical trial, which will be presented at the EHA2025 [1][2]. - Presentations at EHA2025 include findings on the clinical activity and safety of bexobrutideg in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia, scheduled for June 13 and June 14, respectively [6].

Septerna (SEPN) 2025 Conference June 05, 2025 03:45 PM ET Speaker0 Hello, and welcome to the Jefferies twenty twenty five Global Healthcare Conference. My name is Chase Booken with the Jefferies Healthcare Banking team, and it is my great pleasure to introduce Jeff Feiner, CEO of Subturno. Jeff? Speaker1 Okay, thanks Chase and thanks to Jefferies for the invitation to introduce some of you to Subturno for the first time and for others to give you an update. I need to say that my presentation will include so ...